01Approach to the Critical Patient/attcp32

Hemodynamic instability recognition

›Unstable atrial flutter criteria

›Hypotension SBP < 90 mmHg

›Altered mental status

›Acute pulmonary edema

›Signs of cardiogenic shock

›Severe chest pain at rest

›Immediate synchronized cardioversion if unstable

›50-100 J biphasic (flutter often converts at lower energies than AF)

›Class I recommendation, 2015 ACC/AHA/HRS SVT Guideline

›Do not delay cardioversion for anticoagulation in true emergency

›Initiate anticoagulation as soon as possible post-cardioversion

Dangerous rhythm patterns

›High-risk ECG patterns requiring immediate action

›1:1 AV conduction with rate 250-300 bpm

›Life-threatening, can degenerate to VF

›Seen with class IC antiarrhythmics or accessory pathways

›Immediate cardioversion; avoid AV nodal blockers

›Pre-excitation with flutter (WPW)

›Wide QRS, irregular, very rapid

›AV nodal blockers absolutely contraindicated

›Procainamide IV or cardioversion preferred

›Very rapid flutter at 150 bpm concealed by 2:1 block

›Regular narrow complex tachycardia at ~150 bpm — always suspect flutter

Initial stabilization and monitoring

›Monitoring bundle

›Continuous cardiac monitoring and pulse oximetry

›12-lead ECG — confirm flutter, assess for pre-excitation or ischemia

02History/hx54

Symptom characterization

›Cardinal symptoms

›Palpitations

›Rapid, regular pounding sensation

›Abrupt or gradual onset

›Dyspnea

›Exertional vs at rest

›Orthopnea or paroxysmal nocturnal dyspnea (HF decompensation)

›Fatigue and exercise intolerance

›Lightheadedness or presyncope

›Chest discomfort or pain

›Syncope (rare; suggests hemodynamic compromise or 1:1 conduction)

›Onset and duration

›First episode vs recurrent

›Duration < 48 hours vs >= 48 hours

›Critical threshold for anticoagulation before cardioversion

›Spontaneous termination vs persistent

Risk factors and triggers

›Cardiovascular risk factors

›Hypertension

›Coronary artery disease

›Valvular heart disease

›Heart failure (HFrEF and HFpEF)

›Prior cardiac surgery (CABG, valve repair, Fontan, Senning, mitral valve)

›Prior AF or flutter ablation (atypical circuit from scarring)

›Prior cardioversions or antiarrhythmic drug use

›Systemic triggers

›Thyrotoxicosis (heat intolerance, weight loss, tremor)

03Physical Exam/exam35

Vital signs and hemodynamic assessment

›Heart rate and rhythm

›Classic: ~150 bpm regular (2:1 block)

›Variable rates with higher-degree block (75, 100 bpm)

›Irregular rate suggests variable AV block or co-existing AF

›Blood pressure

›Hypotension (SBP < 90 mmHg) — immediate cardioversion threshold

›Pulse pressure narrowing — reduced cardiac output

›Respiratory rate and SpO2

›Tachypnea with pulmonary edema

›Hypoxia suggesting HF or PE

›Temperature

›Fever suggests infection or sepsis as precipitant

Cardiovascular examination

›Cardiac auscultation

›Regular or regularly irregular rhythm (variable block)

›S3 gallop — HF with volume overload

›Murmurs suggesting valvular disease as underlying cause

›Jugular venous distension

›Elevated JVP in HF or RV failure

›Cannon A-waves absent (atria not contracting against closed tricuspid)

›Peripheral edema

›Bilateral pitting edema — HF decompensation

›Unilateral leg swelling — DVT/PE as trigger

Extracardiac examination

›Pulmonary assessment

›Bibasilar crackles — pulmonary edema

›Wheeze — COPD exacerbation as trigger

04Differential Diagnosis/ddx35

Primary rhythm differentials

›Atrial fibrillation (ICD-10: I48)

›Irregularly irregular rhythm

›No organized P waves; chaotic baseline

›Distinguishing: irregular vs regular in atrial flutter

›AVNRT (ICD-10: I47.1)

›Regular narrow-complex tachycardia

›Abrupt onset and offset

›No visible P waves or pseudo-R prime in V1

›Vagal maneuvers or adenosine terminate (vs only slow flutter)

›AVRT with WPW (ICD-10: I45.6)

›Regular narrow or wide complex tachycardia

›Retrograde P waves

›Delta wave on baseline ECG

›Focal atrial tachycardia (ICD-10: I47.1)

›Discrete P waves with isoelectric baseline between them

›P-wave morphology differs from sinus

›Rate typically 150-250 bpm

›Sinus tachycardia (ICD-10: R00.0)

›Gradual onset and offset

›Upright P waves in II with normal PR

›Rate varies with clinical state

›Multifocal atrial tachycardia (ICD-10: I47.1)

›Irregularly irregular

›Three or more distinct P-wave morphologies

›Associated with COPD or electrolyte abnormalities

Secondary and precipitating differentials

›Pulmonary embolism (ICD-10: I26)

05Laboratory Tests/lt28

Core electrolyte and metabolic panel

›Electrolytes (BMP or CMP)

›Potassium — correct to > 4.0 mmol/l before cardioversion

›Hypokalemia increases torsades risk with antiarrhythmics

›Magnesium — correct to >= 1.0 mmol/l before ibutilide or cardioversion

›Mg2+ 2 g IV over 15 minutes if hypomagnesaemia present

›Renal function (creatinine, eGFR)

›Dose adjustment required for dofetilide (renally cleared)

›DOAC dose adjustment thresholds vary by agent

›Thyroid-stimulating hormone

›Rule out thyrotoxicosis as reversible precipitant

›Elevated free T4 with suppressed TSH confirms hyperthyroidism

Cardiac biomarkers and haematology

›Troponin (high-sensitivity)

›Indicated if chest pain or concern for demand ischemia

›Mild elevation common with tachycardia-mediated injury; significant rise suggests ACS

›BNP or NT-proBNP

›HF evaluation and severity stratification

›Guides admission vs discharge decision

›Complete blood count

›Anaemia as high-output trigger

›Baseline before anticoagulation initiation

›Leukocytosis if sepsis is precipitant

Coagulation and anticoagulation assessment

›INR if on warfarin

›Therapeutic INR 2.0-3.0 required for safe cardioversion without TEE

›Subtherapeutic INR at >= 3 weeks requires TEE or delay

›D-dimer

06Diagnostic Tests/dt64

Scoring Systems

›CHA2DS2-VASc score for thromboembolic risk (same criteria as AF)

›Congestive heart failure — 1 point

›Hypertension — 1 point

›Age >= 75 years — 2 points

›Diabetes mellitus — 1 point

›Stroke or TIA history — 2 points

›Vascular disease (prior MI, PAD, aortic plaque) — 1 point

›Age 65-74 years — 1 point

›Sex category female — 1 point

›Score 0 (male) or 1 (female): anticoagulation not recommended

›Score >= 2 (male) or >= 3 (female): anticoagulation recommended

›Class I recommendation, 2023 ACC/AHA/ACCP/HRS AF Guideline

›HAS-BLED score for bleeding risk estimation

›Hypertension, abnormal renal/liver function, stroke, bleeding history

›Labile INR, elderly (> 65), drugs/alcohol

›High score (>= 3) warrants modifiable risk factor correction, not anticoagulation avoidance

MRI

›Cardiac MRI indications in atrial flutter

›Assessment of structural heart disease when TTE inconclusive

›Cardiomyopathy characterization (fibrosis pattern)

›Myocarditis evaluation

›Evaluation of tachycardia-mediated cardiomyopathy

›Quantification of LV function improvement after rate control

›Pre-ablation substrate mapping in atypical flutter

›Scar characterization in post-surgical or post-ablation circuits

›Not indicated for acute diagnosis — ECG is diagnostic for flutter

›Brain MRI if stroke or TIA is suspected complication

CT

›CT pulmonary angiography

›Indicated when PE suspected as flutter precipitant

›Sensitivity ~83-94%, specificity ~96% for acute PE

›Wells PE score >= 5 or PERC-positive: proceed to CTPA

›Coronary CT angiography

›Non-emergent; useful when CAD evaluation needed and patient stable

›Not routinely indicated in acute flutter management

›CT head

›Indicated if focal neurologic symptoms suggesting stroke

›Rule out hemorrhage before thrombolysis if ischemic stroke suspected

›Chest CT (non-contrast)

›Pulmonary pathology evaluation when CXR inconclusive

›Pleural effusion quantification

Ultrasound

›12-lead ECG (primary diagnostic tool)

›Sawtooth flutter waves best seen in leads II, III, aVF

›Negative (inverted) in typical counterclockwise CTI-dependent flutter

›Positive in inferior leads with reverse typical (clockwise) flutter

›Flutter waves visible in V1 as positive deflections in typical flutter

›Atrial rate 250-350 bpm (typically ~300 bpm)

›Ventricular rate ~150 bpm with 2:1 block (most common)

›No isoelectric baseline between flutter waves in inferior leads

›If flutter waves not obvious: adenosine 6-12 mg IV to transiently block AV node

›Point-of-care cardiac ultrasound (POCUS)

›LV function assessment — critical for medication selection

›Reduced EF: avoid CCBs, prefer amiodarone

›Preserved EF: CCBs or beta-blockers first-line

›RV size and function — assess for acute PE or RV failure

›Pericardial effusion

›IVC size and collapsibility for volume status assessment

›Transthoracic echocardiogram (TTE)

›Full structural assessment: LV/RV function, valvular disease, LA size

›LA thrombus has low sensitivity on TTE (~< 50%); TEE preferred

›Required before starting antiarrhythmic medications

›Transesophageal echocardiogram (TEE)

›Required before cardioversion if flutter >= 48 hours or unknown duration and patient not anticoagulated therapeutically for >= 3 weeks

›Superior sensitivity for LA appendage thrombus (95-100%)

›Class IIa recommendation for TEE-guided early cardioversion strategy

›Not required if flutter < 48 hours duration and anticoagulation initiated promptly

07Disposition/dispo28

Admission criteria

›ICU or monitored bed indications

›Hemodynamic instability requiring cardioversion

›1:1 AV conduction or pre-excitation with flutter

›New-onset or decompensated HF

›Refractory to rate control despite multiple agents

›Acute stroke or TIA as flutter complication

›ACS, PE, or sepsis as precipitant requiring inpatient management

›Ibutilide administered — mandatory minimum 4-hour monitored observation

›Dofetilide initiation — requires inpatient QTc monitoring x 3 days

›Uncertain flutter duration requiring TEE before cardioversion

Observation criteria

›Observation unit indications

›New-onset flutter, rate-controlled, awaiting echocardiogram

›Post-cardioversion monitoring in stable patients

›Anticoagulation initiation and first-dose tolerance assessment

›Cardiology or electrophysiology consultation pending

Discharge criteria

›Safe discharge requirements (all must be met)

›Heart rate < 110 bpm at rest, hemodynamically stable

›No hemodynamic instability or syncope

›Anticoagulation initiated or already therapeutic

›Reliable follow-up with cardiology or EP arranged within 1-2 weeks

›No acute precipitant requiring inpatient management

›Known recurrent flutter with established management plan

Electrophysiology consultation triggers

›EP referral indications

›First episode or recurrent symptomatic flutter — CTI ablation discussion

08Treatment/t104

Electrical cardioversion

›Synchronized cardioversion protocol

›Indications: hemodynamic instability or elective rhythm control

›Preferred over chemical cardioversion for reliability

›Class I for unstable, Class IIa for elective in stable flutter

›Energy selection

›50-100 J biphasic for typical flutter

›Flutter often converts at lower energy than AF

›Escalate to 200 J if initial attempt fails

›Sedation for elective cardioversion

›Propofol 1-2 mg/kg IV or midazolam 1-2 mg IV with fentanyl

›Anaesthesia or sedation provider at bedside

›Post-cardioversion management

›Confirm sinus rhythm on 12-lead ECG

›Continue anticoagulation >= 4 weeks regardless of CHA2DS2-VASc score

›Monitor minimum 30-60 minutes post-procedure

Acute rate control

›IV diltiazem (preferred CCB for rate control)

›Indication: preserved LV function (EF >= 40%)

›Loading dose: 0.25 mg/kg IV bolus over 2 minutes

›Repeat 0.35 mg/kg IV bolus after 15 minutes if inadequate response

›Maintenance infusion: 5-15 mg/hr

›Titrate by 2.5-5 mg/hr every 30 minutes to target heart rate < 110 bpm

›Contraindicated in moderate-severe LV systolic dysfunction or decompensated HF

›IV metoprolol (beta-blocker option)

›Indication: preserved LV function

›Dose: 2.5-5 mg IV over 2 minutes

›Repeat every 5 minutes up to 15 mg total

›Rate control onset within 5-10 minutes

›IV esmolol (ultra-short-acting beta-blocker)

›Loading dose: 500 mcg/kg IV bolus over 1 minute

›Maintenance infusion: 50-200 mcg/kg/min

›Titrate by 50 mcg/kg/min every 4 minutes

›Maximum 300 mcg/kg/min

›Offset within 10-20 minutes of discontinuation — useful for rate control titration

›IV amiodarone (reserved for HF or reduced EF)

›Indication: LV systolic dysfunction or decompensated HF where CCBs and beta-blockers contraindicated

›Loading dose: 150 mg IV over 10 minutes

›Maintenance infusion: 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours

›Caution: IV amiodarone contraindicated in pre-excitation flutter (WPW)

›IV digoxin (adjunctive, not preferred)

›Slow onset (6-12 hours); adjunctive role only when other agents contraindicated

›Loading: 0.25-0.5 mg IV, repeat 0.25 mg every 6 hours to total 1-1.5 mg

›Maintenance 0.125-0.25 mg daily

›Rate control often insufficient for flutter alone

›IV magnesium (adjunctive)

›2 g IV over 15 minutes as adjunct to standard rate-control agents

›Reasonable adjunct per 2015 ACC/AHA/HRS SVT Guideline

Chemical cardioversion

›IV ibutilide (preferred pharmacologic cardioversion agent)

›Conversion rate ~60% for atrial flutter

›Dose: 1 mg IV over 10 minutes; repeat once if no conversion after 10 minutes

›Weight < 60 kg: 0.01 mg/kg IV

›Pretreat with magnesium 2 g IV to reduce torsades risk

›Mandatory continuous ECG monitoring for minimum 4 hours post-dose

›Risk of torsades de pointes (2-8%)

›Defibrillator immediately available

›Correct K+ > 4.0 mmol/l and Mg2+ >= 1.0 mmol/l before administration

›Contraindicated if QTc > 440 ms or prior torsades history

›Oral dofetilide (inpatient initiation)

›Effective for atrial flutter conversion and maintenance

›Requires inpatient initiation with 3-day QTc monitoring

›Dose adjusted to renal function (eGFR-based dosing)

›Contraindicated if eGFR < 20 ml/min/1.73m2 or QTc > 440 ms

Anticoagulation strategy

›Duration-based anticoagulation decision

›Flutter < 48 hours with low CHA2DS2-VASc (0-1 male, 1-2 female)

›Cardioversion can proceed; anticoagulate post-cardioversion >= 4 weeks

›Flutter < 48 hours with high CHA2DS2-VASc

›Heparin (UFH or LMWH) or DOAC before cardioversion

›Continue anticoagulation >= 4 weeks post-cardioversion

›Flutter >= 48 hours or unknown duration

›Option 1: Therapeutic anticoagulation >= 3 weeks before cardioversion

›Option 2: TEE to exclude LAA thrombus, then cardioversion with anticoagulation

›Continue anticoagulation >= 4 weeks post-cardioversion in all cases

›Long-term anticoagulation (same as AF strategy)

›Based on CHA2DS2-VASc score

›Preferred agents: DOACs (apixaban, rivaroxaban, dabigatran, edoxaban)

›Apixaban 5 mg PO BID (2.5 mg BID if >= 2 of: age >= 80, weight <= 60 kg, Cr >= 133 mmol/l)

›Rivaroxaban 20 mg PO daily with evening meal (15 mg daily if eGFR 15-49)

›Warfarin if DOAC contraindicated; target INR 2.0-3.0

›Heparin bridging when DOAC not available or contraindicated

›Unfractionated heparin: 80 units/kg IV bolus, then 18 units/kg/hr infusion

›Target aPTT 60-100 seconds

›LMWH enoxaparin 1 mg/kg SC BID as alternative

Definitive therapy — CTI ablation

›Cavotricuspid isthmus (CTI) ablation

›Single-procedure success rate > 90% for typical flutter

›First-line definitive therapy for symptomatic or drug-refractory flutter

›Class I recommendation for recurrent or drug-intolerant typical flutter

›Class IIa for first episode of typical atrial flutter

›Preferred over long-term antiarrhythmic drug therapy

›Post-ablation monitoring

›Continue anticoagulation >= 4 weeks post-ablation

›Long-term anticoagulation based on CHA2DS2-VASc score (AF risk remains)

›Long-term AF monitoring: up to 50% develop AF within years post-ablation

Long-term antiarrhythmic therapy (if ablation not pursued)

›Rhythm control options

›Amiodarone 200 mg PO daily (after loading)

›Most effective but highest side-effect burden (thyroid, pulmonary, hepatic)

›Annual thyroid, LFT, CXR monitoring

›Dofetilide 250-500 mcg PO BID (dose per eGFR)

›QTc monitoring required

›Sotalol 80-160 mg PO BID

›Renally cleared; contraindicated if QTc > 500 ms

›Avoid in significant LV dysfunction

›Rate control agents for long-term management

›Beta-blockers: metoprolol succinate 25-200 mg PO daily or carvedilol 3.125-25 mg PO BID

›Diltiazem ER 120-360 mg PO daily

›Digoxin 0.125-0.25 mg PO daily (adjunctive, especially in HF with reduced EF)

09Special Populations/sp77

Pregnancy

›Physiologic context

›Increased circulating blood volume and heart rate in pregnancy increase arrhythmia risk

›Atrial flutter is uncommon in pregnancy; always evaluate for structural heart disease or thyrotoxicosis

›Thromboembolic risk is elevated in pregnancy independent of CHA2DS2-VASc

›Cardioversion in pregnancy

›Synchronized electrical cardioversion is safe at all stages of pregnancy

›Preferred for unstable flutter or when pharmacologic conversion not feasible

›Fetal monitoring during and after cardioversion recommended

›IV ibutilide: limited data; generally avoided in pregnancy

›Rate control agents in pregnancy

›Beta-blockers (metoprolol, atenolol) — generally preferred; monitor for fetal bradycardia and IUGR

›Atenolol associated with IUGR; avoid if possible in first trimester

›Digoxin — crosses placenta; Category C; relatively safe for rate control

›Diltiazem — limited data; use with caution

›Avoid verapamil in WPW

›Anticoagulation in pregnancy

›DOACs are teratogenic and contraindicated in pregnancy

›Warfarin teratogenic in first trimester; avoid 6-12 weeks gestation

›Low-molecular-weight heparin (enoxaparin) preferred throughout pregnancy

›Enoxaparin 1 mg/kg SC BID; anti-Xa monitoring in high-risk pregnancies

›Unfractionated heparin peripartum (does not cross placenta)

›CTI ablation in pregnancy

›Defer to post-partum period whenever possible

›If necessary, use electroanatomic mapping to minimize fluoroscopy

Geriatric

›Epidemiology and risk

›Prevalence increases sharply with age; atrial flutter affects 88 per 100,000 persons; rate highest in > 80 years

›Higher burden of comorbidities: CAD, HF, CKD, valvular disease

›Increased risk of tachycardia-mediated cardiomyopathy in elderly due to reduced cardiac reserve

›Rate control considerations

›Lower doses of AV nodal agents to avoid excessive bradycardia or hypotension

›Diltiazem: start with low-dose IV (0.15-0.20 mg/kg) in frail elderly

›Beta-blockers: increased sensitivity; start at lowest dose

›Digoxin has narrow therapeutic window; monitor levels; target 0.5-0.9 nmol/l

›Anticoagulation in geriatric patients

›Age >= 75 adds 2 points to CHA2DS2-VASc; most elderly patients warrant anticoagulation

›Increased bleeding risk: falls, frailty, polypharmacy, CKD

›HAS-BLED assessment essential; high score prompts risk-factor modification, not anticoagulation avoidance

›Dose-reduced DOACs for age and renal function (apixaban 2.5 mg BID if criteria met)

›Avoid dabigatran in CrCl < 30 ml/min

›Ablation in elderly patients

›CTI ablation safe and effective in elderly; age alone not a contraindication

›Procedural risk increased with multiple comorbidities; individualize decision

›Cardioversion in elderly

›Higher energy may be required due to increased chest wall impedance

›Sedation doses reduced; monitor for prolonged sedation effect

Pediatrics

›Epidemiology and aetiology

›Atrial flutter in neonates and infants: most common sustained tachyarrhythmia in first 48 hours of life

›Neonatal flutter: often idiopathic; frequently resolves spontaneously after cardioversion

›Older children and adolescents: associated with congenital heart disease (especially post-surgical repair — Fontan, Mustard, Senning, ToF repair)

›Structural heart disease evaluation mandatory in all pediatric flutter

›Presentation in neonates

›Fetal hydrops or fetal tachycardia on prenatal ultrasound

›Poor feeding, irritability, pallor, respiratory distress

›Atrial rate 300-600 bpm in neonates (higher than adult rates)

›Typically 2:1 or 3:1 block producing ventricular rate 150-250 bpm

›Cardioversion in pediatrics

›Synchronized electrical cardioversion: first-line for hemodynamic compromise

›0.5-1 J/kg initial, escalate to 2 J/kg

›Neonatal cardioversion: often effective at 0.5 J/kg

›Transesophageal rapid atrial pacing: effective alternative in neonates with esophageal pacing

›Pharmacologic management in pediatrics

›IV adenosine: diagnostic to unmask flutter waves; does not terminate flutter

›0.1 mg/kg IV rapid push (max 6 mg first dose)

›IV digoxin: used for rate control in neonates and infants

›Loading: 10 mcg/kg IV then 5 mcg/kg IV x 2 doses every 8 hours

›Maintenance 5-10 mcg/kg/day divided BID

›IV amiodarone: for hemodynamically unstable refractory cases

›5 mg/kg IV over 20-60 minutes

›IV ibutilide and dofetilide: limited pediatric data; avoid in young children

›Anticoagulation in pediatrics

›Thromboembolic risk lower in isolated neonatal flutter

›Anticoagulation guided by duration, structural heart disease, and haemodynamic status

›Enoxaparin weight-based dosing: < 2 kg neonates 0.75 mg/kg SC BID; > 2 kg 0.5 mg/kg SC BID

›Long-term management in pediatrics

›Neonatal flutter without structural disease: low recurrence after cardioversion; may not require long-term therapy

›Congenital heart disease flutter: high recurrence; ablation or antiarrhythmic therapy required

›CTI ablation feasible in children > 15 kg; hybrid surgical-catheter approaches for complex congenital circuits

10Background/b50

Epidemiology

›Incidence and prevalence

›Estimated incidence 88 per 100,000 person-years in general population

›Prevalence increases sharply with age; rare in those < 50 years

›Male predominance: incidence 2.5x higher in men than women

›Second most common pathologic supraventricular tachycardia after AVNRT

›Associated conditions

›Up to 50% of patients with atrial flutter will develop AF over long-term follow-up

›Up to 82% develop AF after CTI ablation when monitored long-term

›Shares identical thromboembolic risk profile with AF

›Tachycardia-mediated cardiomyopathy occurs in persistent uncontrolled flutter; reversible with rate or rhythm control

›Mortality and morbidity

›Annual stroke risk mirrors AF by CHA2DS2-VASc score

›Mortality primarily driven by underlying cardiac disease and thromboembolic complications

Pathophysiology

›Typical atrial flutter mechanism (ICD-10: I48.3)

›Macroreentrant circuit around the tricuspid annulus

›Counterclockwise conduction in typical flutter (most common > 90% of cases)

›Critical isthmus: cavotricuspid isthmus (CTI) between tricuspid annulus and inferior vena cava

›Clockwise (reverse typical) flutter: less common; positive flutter waves in inferior leads

›Atrial rate 250-350 bpm (typically ~300 bpm)

›AV node serves as gatekeeper; 2:1 block most common yielding ventricular rate ~150 bpm

›Higher degree block (3:1, 4:1) produces slower ventricular rates (75-100 bpm)

›Variable block produces irregularly irregular rhythm

›Atypical flutter

›Non-CTI-dependent circuits; typically post-cardiac surgery or post-ablation scar

›Fontan baffle circuits, mitral annular flutter, scar-based right or left atrial flutter

›Atrial rates may be slower (200-250 bpm)

11Patient Discharge Instructions/pdi29

copy discharge instructions

›Discharge instructions for atrial flutter

›Diagnosis and description

›Your heart was beating in an abnormal rhythm called atrial flutter

›Your heart was beating too fast (about 150 beats per minute)

›Treatment was given to slow or restore your heart rate

›Medications — take as prescribed

›Rate control medication (beta-blocker or diltiazem): take every day even if feeling well

›Blood thinner (anticoagulant): take every day to reduce stroke risk; do not miss doses

›Do not stop any heart medication without talking to your doctor first

›Activity and lifestyle

›Avoid alcohol — it is a known trigger for atrial flutter

›Limit or avoid caffeine if it triggers symptoms

›Stay well hydrated

›Resume light activity as tolerated; avoid strenuous exercise until cleared by cardiologist

›Follow-up appointments

›See your cardiologist or heart rhythm specialist (electrophysiologist) within 1-2 weeks

›Discuss whether a heart procedure called ablation is right for you — it can cure flutter in over 90% of cases

›Bring your medication list to every appointment

›Bleeding precautions if on blood thinners

›Use a soft-bristle toothbrush and electric razor

›Avoid NSAIDs (ibuprofen, naproxen) unless approved by your doctor

›Tell all doctors and dentists that you are on a blood thinner before any procedure

›Return to the emergency department immediately for

›Rapid heart racing, pounding, or fluttering in the chest

›Fainting or near-fainting

›Severe shortness of breath or chest pain

›Facial drooping, arm weakness, speech difficulty, or sudden vision change (signs of stroke)

12References/r15

Guidelines and key sources

›Primary guidelines

›2015 ACC/AHA/HRS Guideline for Management of Adult Patients With Supraventricular Tachycardia — Page RL et al., JACC 2016 (Class I/IIa/IIb recommendations for flutter management and ablation)

›2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation — Joglar JA et al., JACC 2024 (anticoagulation and CHA2DS2-VASc strategy applied to flutter)

›2019 AHA/ACC/HRS Focused Update of 2014 AF Guideline — January CT et al., Heart Rhythm 2019

›2020 AHA Guidelines for CPR and Emergency Cardiovascular Care — Panchal AR et al., Circulation 2020 (cardioversion protocols)

›2025 AHA Guidelines for Adult Advanced Life Support — Wigginton JG et al., Circulation 2025

›Landmark texts and reviews

›Link MS. Evaluation and Initial Treatment of Supraventricular Tachycardia. NEJM 2012

›Hanna E. Atrial Flutter and Atrial Tachycardia. Practical Cardiovascular Medicine 2e. 2022

›Peng G, Zei PC. Diagnosis and Management of Paroxysmal SVT. JAMA 2024

›Blomstrom-Lundqvist C et al. ACC/AHA/ESC Guidelines for Management of SVT — Executive Summary. JACC 2003

›ECG and electrophysiology references

›Bayes De Luna A et al. Diagnosis of Arrhythmias in Clinical Practice. Clinical Electrocardiography 2021

›Bayes De Luna A et al. Active Supraventricular Arrhythmias. Clinical Electrocardiography 2021

›Hanna E. Approach to Narrow and Wide QRS Complex Tachyarrhythmias. Practical Cardiovascular Medicine 2e. 2022

Evidence & Review

Evidence & Review